 | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular,Intranasal |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
Razi Cov Pars (Persian:رازی کوو پارس) is aCOVID-19 vaccine developed by the IranianRazi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.[1][2][3]It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently inphase III ofclinical research during which it's compared to theSinopharm BIBP vaccine.[4][5]
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3]
Razi Cov Pars is arecombinant proteinsubunit vaccine containing the SARS-CoV-2spike protein.[2]
It's planned to produce one million doses of the vaccine each month as of September 2021.[4]
As of 25 November 2021, 5 millions doses have been delivered to theIranian Ministry of Health.[6]
| Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
|---|---|---|---|---|---|---|---|
| Total | Vaccine | Placebo | |||||
| I | IRCT20201214049709N1 | 21 January 2021 | 133 | 30(5 μg/200 μL) 30(10 μg/200 μL) 30(20 μg/200 μL) | 30(placebo) 13(sentinel) | 18-50 years | [2] |
| II | IRCT20201214049709N2 | 13 April 2021 | 500 | 18-70 years | [3] | ||
| III | IRCT20201214049709N3Archived 30 August 2021 at theWayback Machine | 29 August 2021 | 41,128 | 20,564 | 0(placebo) 20,564(Sinopharm BIBP vaccine) | 18+ years | [5] |
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
